TRDAEntrada Therapeutics, Inc.

Nasdaq entradatx.com


$ 16.12 $ 1.01 (6.68 %)    

Tuesday, 28-May-2024 15:59:55 EDT
QQQ $ 454.82 $ 1.73 (0.38 %)
DIA $ 398.57 $ -2.04 (-0.52 %)
SPY $ 530.36 $ 0.37 (0.07 %)
TLT $ 91.26 $ -1.31 (-1.43 %)
GLD $ 225.37 $ 2.27 (1.05 %)
$ 16.14
$ 15.50
$ 16.09 x 200
$ 0.00 x 0
$ 15.41 - $ 16.20
$ 10.62 - $ 18.44
141,161
na
561.53M
$ 0.80
$ 21.82
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 03-13-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-06-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-15-2022 12-31-2021 10-K
11 12-09-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 insiders-buying-americas-car-mart-and-2-other-stocks

Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.

 around-5m-bet-on-this-communication-services-stock-check-out-these-4-stocks-insiders-are-buying

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

 hc-wainwright--co-reiterates-buy-on-entrada-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $2...

 entrada-therapeutics-q4-gaap-eps-029-misses-017-estimate-sales-4185m-beat-2369m-estimate

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate o...

 oppenheimer-initiates-coverage-on-entrada-therapeutics-with-outperform-rating-announces-price-target-of-22

Oppenheimer analyst Hartaj Singh initiates coverage on Entrada Therapeutics (NASDAQ:TRDA) with a Outperform rating and annou...

 hc-wainwright--co-maintains-buy-on-entrada-therapeutics-lowers-price-target-to-20

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the pr...

 why-is-neuromuscular-disease-focused-entrada-therapeutics-shares-trading-lower-today

Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in 

 entrada-therapeutics-q3-eps-102-may-not-be-comparable-to-074-estimate-sales-4373m-may-not-be-comparable-to-960m-estimate

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly earnings of $1.02 per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-entrada-therapeutics-maintains-25-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $2...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION